Twenty-First Century Global ADR Management: A Need for Clarification, Redesign, and Coordinated Action

Area of Science:

• Pharmacovigilance and Public Health
• Drug Safety and Risk Management

Background:

• Adverse drug reactions (ADRs) rank among the top causes of death globally, impacting diverse populations and causing significant morbidity.
• Current medicines risk management heavily relies on outdated signal detection in large databases, which have limitations in scope and timeliness.
• Existing databases primarily focus on short-term reactions, failing to capture broader, long-term consequences of medication use.

Purpose of the Study:

• To highlight the limitations of current adverse drug reaction (ADR) detection and management strategies.
• To advocate for the development of novel tools and methodologies for earlier and more comprehensive ADR identification.
• To emphasize the integration of medicines risk management into a broader global public health framework.

Main Methods:

• Critical review of existing pharmacovigilance databases and signal detection methodologies.
• Analysis of the limitations of current approaches in assessing the full spectrum of ADRs.
• Conceptualization of new strategies for proactive and integrated medicines risk management.

Main Results:

• Current signal detection methods in large ADR databases are antiquated and have reached their limits.
• Existing databases are insufficient for assessing the broader geographical, temporal, and clinical consequences of ADRs.
• There is a critical need for new tools and methodologies to improve early identification and management of ADRs.

Conclusions:

• Medicines risk management requires a paradigm shift from reactive signal detection to proactive, integrated public health strategies.
• Developing innovative tools is essential for earlier and more regular identification of overlooked ADRs.
• Integrating medicines risk management into global public health is crucial for addressing current and future health challenges, including pandemics.